Glucocorticoid-Induced Skin Atrophy: The Old and the New

References

• Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42–54. doi:10.1016/j.tem.2017.10.01029162310
   PubMed Web of Science ®Google Scholar
• Chung YS, Jin HL, Jeong KW. Cell-specific expression of ENACα gene by FOXA1 in the glucocorticoid receptor pathway. Int J Immunopathol Pharmacol. 2020;34:2058738420946192. doi:10.1177/205873842094619232838581
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365(9461):801–803. doi:10.1016/S0140-6736(05)17989-615733723
   PubMed Web of Science ®Google Scholar
• Cheah JTL, Robson JC, Black RJ, et al. The patient’s perspective of the adverse effects of glucocorticoid use: a systematic review of quantitative and qualitative studies. From an OMERACT working group. Semin Arthritis Rheum. 2020;50(5):996–1005. doi:10.1016/j.semarthrit.2020.06.01932911291
   PubMed Web of Science ®Google Scholar
• Christiansen JJ, Djurhuus CB, Gravholt CH, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007;92(9):3553–3559. doi:10.1210/jc.2007-044517609300
   PubMed Web of Science ®Google Scholar
• Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11):1500–1510. doi:10.1016/j.metabol.2011.06.01221864867
   PubMed Web of Science ®Google Scholar
• Kraft M, Soost S, Worm M. Chapter 95. Topical and systemic corticosteroids In: John SM, Johansen JD, Rustemeyer T, Elsner P, Maibach HI, editors. Kanerva’s Occupational Dermatology. 3rd ed. Switzerland: Springer Nature; 2020:1433–1439.
   Google Scholar
• Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2019;49(2):251–259. doi:10.1016/j.semarthrit.2019.03.01030987856
   PubMed Web of Science ®Google Scholar
• Cain DW, Cidlowski JA. Specificity and sensitivity of glucocorticoid signaling in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29(4):545–556. doi:10.1016/j.beem.2015.04.00726303082
   PubMed Web of Science ®Google Scholar
• Tatu AL, Nwabudike LC The treatment options of male genital lichen sclerosus et atrophicus. Short Title for a Running Head: treatments of genital lichen sclerosus. Proceedings of the 14th national congress of Urogynecology and the national conference of the Romanian Association for the Study of Pain; 2017 907–09; Eforie, Romania 2017:262–264.
   Google Scholar
• Tatu AL, Nwabudike LC. Male genital lichen sclerosus — a permanent therapeutic challenge. J Am Acad Dermatol. 2018;79(3 Supplement 1):AB185.
   Web of Science ®Google Scholar
• Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008;68(3):453–466. doi:10.1016/j.ejpb.2007.08.00717826047
   PubMed Web of Science ®Google Scholar
• Coondoo A, Chattopadhyay C. Use and abuse of topical corticosteroids in children. Indian J Paediatr Dermatol. 2014;15:1–4. doi:10.4103/2319-7250.131826
   Google Scholar
• Vitellius G, Trabado S, Bouligand J, Delemer B, Lombès M. Pathophysiology of glucocorticoid signaling. Ann Endocrinol (Paris). 2018;79(3):98–106. doi:10.1016/j.ando.2018.03.00129685454
   PubMed Web of Science ®Google Scholar
• Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol Annu Rev. 2006;12:269–300.17045197
   PubMedGoogle Scholar
• Sainte Marie Y, Toulon A, Paus R, et al. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol. 2007;171(3):846–860. doi:10.2353/ajpath.2007.06099117675581
   PubMed Web of Science ®Google Scholar
• Lesovaya E, Agarwal S, Readhead B, et al. Rapamycin modulates glucocorticoid receptor function, blocks atrophogene REDD1, and protects skin from steroid atrophy. J Invest Dermatol. 2018;138(9):1935–1944. doi:10.1016/j.jid.2018.02.04529596905
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Farman N, Maubec E, et al. Re-epithelialization of pathological cutaneous wounds is improved by local mineralocorticoid receptor antagonism. J Invest Dermatol. 2016;136(10):2080–2089. doi:10.1016/j.jid.2016.05.10127262545
   PubMed Web of Science ®Google Scholar
• Maubec E, Laouénan C, Deschamps L, et al. Topical mineralocorticoid receptor blockade limits glucocorticoid-induced epidermal atrophy in human skin. J Invest Dermatol. 2015;135(7):1781–1789. doi:10.1038/jid.2015.4425668238
   PubMed Web of Science ®Google Scholar
• Sevilla LM, Pérez P. Roles of the glucocorticoid and mineralocorticoid receptors in skin pathophysiology. Int J Mol Sci. 2018;19(7):1906. doi:10.3390/ijms19071906
   PubMed Web of Science ®Google Scholar
• Røpke MA, Alonso C, Jung S, et al. Effects of glucocorticoids on stratum corneum lipids and function in human skin – a detailed lipidomic analysis. J Dermatol Sci. 2017;88(3):330–338. doi:10.1016/j.jdermsci.2017.08.00928911799
   PubMed Web of Science ®Google Scholar
• Agarwal S, Mirzoeva S, Readhead B, Dudley JT, Budunova I. PI3K inhibitors protect against glucocorticoid-induced skin atrophy. EBioMedicine. 2019;41:526–537. doi:10.1016/j.ebiom.2019.01.05530737086
   PubMed Web of Science ®Google Scholar
• Baida G, Bhalla P, Yemelyanov A, et al. Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy. Oncotarget. 2018;9(78):34772–34783. doi:10.18632/oncotarget.2619430410676
   PubMedGoogle Scholar
• Terao M, Katayama I. Local cortisol/corticosterone activation in skin physiology and pathology. J Dermatol Sci. 2016;84(1):11–16. doi:10.1016/j.jdermsci.2016.06.01427431412
   PubMed Web of Science ®Google Scholar
• Slominski AT, Zmijewski MA. Glucocorticoids inhibit wound healing: novel mechanism of action. J Invest Dermatol. 2017;137(5):1012–1014. doi:10.1016/j.jid.2017.01.02428411834
   PubMed Web of Science ®Google Scholar
• Slominski AT, Brożyna AA, Tuckey RC. Cutaneous glucocorticoidogenesis and cortisol signaling are defective in psoriasis. J Invest Dermatol. 2017;137(8):1609–1611. doi:10.1016/j.jid.2017.04.00428735612
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729. doi:10.1007/s00403-014-1485-325027750
   PubMed Web of Science ®Google Scholar
• Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev. 2013;12(5):629–632. doi:10.1016/j.autrev.2012.12.00223261815
   PubMed Web of Science ®Google Scholar
• Korting HC, Kerscher MJ, Schäfer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol. 1992;27(1):87–92. doi:10.1016/0190-9622(92)70162-91619082
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ionescu MA, Clatici VG, Cristea VC. Bacillus cereus strain isolated from Demodex folliculorum in patients with topical steroid-induced rosaceiform facial dermatitis. An Bras Dermatol. 2016;91:676–678. doi:10.1590/abd1806-4841.2016521427828651
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ionescu MA, Nwabudike LC. Contact allergy to topical mometasone furoate confirmed by rechallenge and patch test. Am J Ther. 2018;25(4):e497–e498. doi:10.1097/MJT.000000000000058128328785
   PubMed Web of Science ®Google Scholar
• Tatu AL, Ciobotaru OR, Miulescu M, et al. Hydrochlorothiazide: chemical structure, therapeutic, phototoxic and carcinogenetic effects in dermatology. REV CHIM (Bucharest). 2018;69(8):2110–2114. doi:10.37358/RC.18.8.6484
   Web of Science ®Google Scholar
• Nwabudike LC, Elisei AM, Buzia OD, Miulescu M, Tatu AL. Statins. A review on structural perspectives, adverse reactions and relations with non-melanoma skin cancer. REV CHIM (Bucharest). 2018;69(9):2557–2562. doi:10.37358/RC.18.9.6575
   Web of Science ®Google Scholar
• Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin (Review). Exp Ther Med. 2019;18(2):955–959. doi:10.3892/etm.2019.750431384329
   PubMed Web of Science ®Google Scholar
• Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. 2014;59(5):456–459. doi:10.4103/0019-5154.13987225284849
   PubMed Web of Science ®Google Scholar
• DeFranco DB. Chaperoning skin atrophy. Oncotarget. 2018;9(92):36407–36408. doi:10.18632/oncotarget.2637530559924
   PubMedGoogle Scholar
• Löfberg E, Gutierrez A, Wernerman J, et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur J Clin Invest. 2002;32(5):345–353. doi:10.1046/j.1365-2362.2002.00993.x12027875
   PubMed Web of Science ®Google Scholar
• Burt MG, Johannsson G, Umpleby AM, Chisholm DJ, Ho KKY. Impact of acute and chronic low-dose glucocorticoids on protein metabolism. J Clin Endocrinol Metab. 2007;92(10):3923–3929. doi:10.1210/jc.2007-095117652216
   PubMed Web of Science ®Google Scholar
• Hasan KM, Rahman MS, Arif KM, Sobhani ME. Psychological stress and aging: role of glucocorticoids (GCs). Age (Dordr). 2012;34(6):1421–1433. doi:10.1007/s11357-011-9319-021971999
   PubMedGoogle Scholar
• Gauthier A, Fisch A, Seuwen K, et al. Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. Biomaterials. 2018;178:481–495. doi:10.1016/j.biomaterials.2018.04.00629650255
   PubMed Web of Science ®Google Scholar
• Schwartz E, Mezick JA, Gendimenico GJ, Kligman LH. In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. J Invest Dermatol. 1994;102(2):241–246. doi:10.1111/1523-1747.ep123717708106754
   PubMed Web of Science ®Google Scholar
• Jung S, Lademann J, Darvin M, et al. Structural changes in human skin after topical application of glucocorticoids assessed by in vivo imaging technologies. J Invest Dermatol. 2017;137(5):S46. doi:10.1016/j.jid.2017.02.288
   Web of Science ®Google Scholar
• Chebotaev DV, Yemelyanov AY, Lavker RM, Budunova IV. Epithelial cells in the hair follicle bulge do not contribute to epidermal regeneration after glucocorticoid-induced cutaneous atrophy. J Invest Dermatol. 2007;127(12):2749–2758. doi:10.1038/sj.jid.570099217657244
   PubMed Web of Science ®Google Scholar
• Ahn SK, Bak HN, Park BD, et al. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. J Dermatol. 2006;33(2):80–90. doi:10.1111/j.1346-8138.2006.00018.x16556273
   PubMed Web of Science ®Google Scholar
• Baida G, Agarwal S, Readhead B, Dudley JT, Budunova I. Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin. Oncotarget. 2020;11(4):409–418. doi:10.18632/oncotarget.2744532064044
   PubMedGoogle Scholar
• Quinn M, Ramamoorthy S, Cidlowski JA. Sexually dimorphic actions of glucocorticoids: beyond chromosomes and sex hormones. Ann Acad NY Sci. 2014;1317:1–6. doi:10.1111/nyas.12425
   PubMed Web of Science ®Google Scholar
• Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. JAAD. 2015;72(3):541–549. doi:10.1016/j.jaad.2014.11.02425592622
   PubMed Web of Science ®Google Scholar
• Jakhar D, Kaur I. Dermoscopy of topical steroid damaged/dependent face. Indian Dermatol Online J. 2018;9(4):286–287. doi:10.4103/idoj.IDOJ_301_1730050829
   PubMedGoogle Scholar
• Tatu AL. Topical steroid induced facial rosaceiform dermatitis. Acta Endo (Buc). 2016;12:232–233. doi:10.4183/aeb.2016.232
   Web of Science ®Google Scholar
• Tatu AL, Clătici V. Some correlations between the clinical and dermoscopic features of steroid induced facial dermatitis (abstract). J Am Acad Dermatol. 2015;72(5 Supplement 1):AB91.
   Web of Science ®Google Scholar
• Bower AJ, Arp Z, Zhao Y, et al. Longitudinal in vivo tracking of adverse effects following topical steroid treatment. Exp Dermatol. 2016;25(5):362–367. doi:10.1111/exd.1293226739196
   PubMed Web of Science ®Google Scholar
• Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–420. doi:10.1111/j.0906-6705.2006.00435.x16689857
   PubMed Web of Science ®Google Scholar
• Ilie MA, Caruntu C, Lixandru D, et al. In vivo confocal laser scanning microscopy imaging of skin inflammation: clinical applications and research directions (Review). Exp Ther Med. 2019;17:1004–1011. doi:10.3892/etm.2018.698130679966
   PubMed Web of Science ®Google Scholar
• Boudon SM, Vuorinen A, Geotti-Bianchini P, et al. Novel 11β-hydroxysteroid dehydrogenase 1 inhibitors reduce cortisol levels in keratinocytes and improve dermal collagen content in human ex vivo skin after exposure to cortisone and UV. PLoS One. 2017;12(2):e0171079. doi:10.1371/journal.pone.017107928152550
   PubMed Web of Science ®Google Scholar
• Dyer JM, Miller RA. Chronic skin fragility of aging: current concepts in the pathogenesis, recognition, and management of dermatoporosis. J Clin Aesthet Dermatol. 2018;11(1):13–18.
   PubMedGoogle Scholar
• Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995;162(2):123–126.7794369
   PubMedGoogle Scholar
• Schoepe S, Schäcke H, Asadullah K. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol. 2011;3(3):175–179. doi:10.4161/derm.1506522110776
   PubMedGoogle Scholar
• Dack KN, Johnson PS, Henriksson K, et al. Topical ‘dual-soft’ glucocorticoid receptor agonist for dermatology. Bioorg Med Chem Lett. 2020;30(17):127402. doi:10.1016/j.bmcl.2020.12740232738970
   PubMed Web of Science ®Google Scholar
• Klopot A, Baida G, Bhalla P, Haegeman G, Budunova I. Selective activator of the glucocorticoid receptor compound a dissociates therapeutic and atrophogenic effects of glucocorticoid receptor signaling in skin. J Cancer Prev. 2015;20(4):250–259. doi:10.15430/JCP.2015.20.4.25026734587
   PubMedGoogle Scholar
• Boix J, Nguyen VT, Farman N, Aractingi S, Pérez P. Mineralocorticoid receptor blockade improves glucocorticoid-induced skin atrophy but partially ameliorates anti-inflammatory actions in an irritative model in human skin explants. Exp Dermatol. 2018;27(2):185–187. doi:10.1111/exd.1347329178328
   PubMed Web of Science ®Google Scholar
• Elliott L, Rashid RM, Colome M. Hyaluronic acid filler for steroid atrophy. J Cosmet Dermatol. 2010;9(3):253–255. doi:10.1111/j.1473-2165.2010.00508.x20883302
   PubMed Web of Science ®Google Scholar
• Di Gregorio C, D’Arpa S. Therapeutic use of hyaluronic acid fillers in the treatment of corticosteroid-induced skin and subcutaneous atrophy. Dermatol Surg. 2016;42(11):1307–1310. doi:10.1097/DSS.000000000000081027399950
   PubMed Web of Science ®Google Scholar
• Ardeleanu V, Dobre M, Georgescu EM. Deep facial wrinkle treatment outcome after first injection of reticulated hyaluronic acid. REV CHIM (Bucharest). 2015;66(12):2129–2131.
   Web of Science ®Google Scholar
• Niculet E, Radaschin DS, Nastase F, et al. Influence of phytochemicals in induced psoriasis (Review). Exp Ther Med. 2020;20:3421–3424. doi:10.3892/etm.2020.901332905089
   PubMed Web of Science ®Google Scholar
• Niculet E, Neculia GV, Tatu AL, Buzia OD. Curcumin-extraction, physical and chemical analysis,formulas and control. Basic methods for further research. Mat Plast. 2018;55(4):672–675. doi:10.37358/MP.18.4.5110
   Web of Science ®Google Scholar
• Fawzy S, Ahmed N, Eldin Elshafie M, Radwan S. Effect of curcumin versus hyaluronic acid on glucocorticoid induced skin atrophy and subsequent skin abrasions in rats. Egypt J Histol. 2019;42(1):35–50. doi:10.21608/ejh.2018.6166.1037
   Google Scholar